Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS Guidelines
  • Expert Panel Reaffirms...

Expert Panel Reaffirms Beta-blockers as First-Line Therapy for Hypertension in India

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-12-07T08:45:19+05:30  |  Updated On 7 Dec 2024 11:44 AM IST
Expert Panel Reaffirms Beta-blockers as First-Line Therapy for Hypertension in India
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

India: An expert panel in India came together to develop a consensus on the role of beta-blockers in managing hypertension. The Indian consensus, published in the Journal of the Association of Physicians of India (JAPI), developed graded recommendations regarding the clinical role of beta-blockers in managing hypertension (HTN), HTN with additional cardiovascular (CV) risk, and type 2 diabetes mellitus (T2DM).

Hypertension, a condition affecting millions worldwide, remains a significant health challenge, especially in India, where early cardiovascular disease (CVD) is a growing concern. Despite advances in treatment, the management of essential hypertension continues to be difficult, with control achieved in fewer than 1 in 10 cases, particularly when aligned with updated guidelines from the American College of Cardiology (ACC) and the International Society of Hypertension (ISH). In response to these challenges, the positioning of beta-blockers, particularly nebivolol, has evolved, with a focus on their relevance to the Indian population's unique characteristics, including premature CVD, fragile coronary architecture, and high resting heart rates.

The panel, comprising clinical and interventional cardiologists, synthesized current evidence to provide graded recommendations based on guidelines, including the 2023 updates of the European Society of Hypertension (ESH). The Indian consensus aims to clarify the clinical role of beta-blockers in treating hypertension, particularly when compounded by comorbid conditions such as T2DM and cardiovascular risk factors.

The consensus findings emphasize the pivotal role of beta-blockers, including nebivolol, in hypertension management. An overwhelming 94% of the panelists agreed that the 2023 ESH hypertension guidelines have increased confidence in the use of beta-blockers as a first-line therapy for HTN. In particular, beta-blockers are recommended for individuals with hypertension who exhibit high resting heart rates, such as younger hypertensive patients under the age of 40. Moreover, for those under 60 years old, regardless of comorbid conditions, beta-blockers are considered the preferred drug choice.

For hypertensive patients with T2DM, 95% of the experts favored nebivolol due to its beneficial effects in managing both hypertension and diabetes. Nebivolol was also deemed the most suitable beta-blocker for patients with angina, with metoprolol and bisoprolol following closely behind in preference. In patients with chronic obstructive pulmonary disease (COPD) and hypertension, nebivolol was once again the most preferred option, as it tends to cause fewer pulmonary side effects compared to other beta-blockers.

The study also highlighted the importance of combining nebivolol with angiotensin receptor blockers (ARBs) in patients who do not respond well to ARB monotherapy. This combination therapy was shown to be particularly effective for hypertensive patients with diabetes and those suffering from ischemic heart disease (IHD), such as those presenting with angina or myocardial infarction (MI).

Consensus on the Role of Beta-blockers in Hypertension Treatment

  1. First-line Treatment
    Beta-blockers are classified as first-line drugs for the treatment of hypertension (HTN).
    • 94% of respondents stated that the updated ESH HTN guidelines (2023) have increased confidence in using beta-blockers for HTN management.
  2. Beta-blockers in Comorbid Conditions
    Beta-blockers are recommended in the treatment of HTN, particularly for patients with comorbid conditions such as myocardial infarction (MI), heart failure with reduced ejection fraction (HFrEF), and atrial fibrillation (AF).
    • They are also beneficial in patients with high resting heart rates, providing additional protection.
  3. High Resting Heart Rates
    Beta-blockers should be prescribed to patients with HTN who have high resting heart rates, including younger hypertensives under the age of 40.
  4. Resting Heart Rate and Blood Pressure
    In the general population, resting heart rate is a significant predictor of blood pressure and mortality risk.
    • Beta-blockers are recommended for patients under 60 years of age with HTN, regardless of the presence of comorbid diseases.
  5. Nebivolol in Hypertensive Patients with Diabetes
    Nebivolol is the most preferred beta-blocker for hypertensive patients with diabetes.
    • Other commonly preferred options include bisoprolol and metoprolol.
  6. Beta-blockers in COPD and HTN
    Nebivolol is the preferred beta-blocker for patients with both chronic obstructive pulmonary disease (COPD) and HTN due to its favorable side effect profile.
  7. Nebivolol + ARB Combination
    The combination of nebivolol and angiotensin receptor blockers (ARBs) can be considered in:
    • Patients who do not respond well to ARB monotherapy
    • Hypertensive patients with diabetes
    • Patients with HTN and ischemic heart disease (IHD), particularly those experiencing angina or myocardial infarction (MI).

"The consensus firmly places beta-blockers, especially nebivolol, at the forefront of hypertension treatment in India. The findings support their use in various patient subsets, including those with high resting heart rates, younger hypertensives, and patients with comorbid conditions like T2DM and COPD. Given the unique health challenges in India, these updated recommendations provide a comprehensive approach to managing hypertension, ensuring better long-term outcomes for patients," the researchers concluded.

Reference:

Mohan JC, Roy DG, Ray S, et al. Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus. J Assoc Physicians India 2024;72(10):83-90.

Journal of the Association of Physicians of India (JAPI)hypertensionbeta-blockerscardiovascular diseasenebivolol
Source : Journal of the Association of Physicians of India (JAPI)
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    View All

    Journal Club Today

    Study Reveals Why Your Immune System Works Better in Daylight

    Study Reveals Why Your Immune System Works Better in Daylight

    View All

    Health News Today

    Health Bulletin 29/May/2025

    Health Bulletin 29/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok